Table 3 Open in new tab Electrical...

Baseline

IVR

RVA

CRT

ȃPP

560.3 ± 68.8

516.3 ± 77.2

533.5 ± 53.8

ȃRR

1338.0 ± 361.2

1000.0 ± 0.0*

ȃQRS

98.8 ± 4.6

118.8 ± 10.1*

95.6 ± 5.9**

ȃQT

386.4 ± 67.0

379.6 ± 37.6

337.0 ± 24.6

ȃQTc

357.0 ± 56.5

379.6 ± 37.6

337.0 ± 24.6

ȃJTc

258.2 ± 56.2

260.8 ± 35.3

241.3 ± 24.6

ȃTp-e

82.6 ± 35.2

67.2 ± 15.0

61.9 ± 17.5

ȃRV_AT

26.9 ± 4.6

46.0 ± 6.1*

ȃLV_AT

35.8 ± 12.8

64.6 ± 8.3*

43.6 ± 8.3**

ȃΔAT

37.6 ± 8.1

−2.4 ± 9.6**

ȃRV MAPD

242.1 ± 16.0

221.6 ± 15.7**

ȃLV ARI

324.8 ± 51.0

271.2 ± 24.1*

266.0 ± 21.2*

ȃΔMAPD

30.0 ± 12.7

44.4 ± 14.7

ȃRV STV

1.1 ± 0.3

1.4 ± 0.7

ȃLV STV

3.2 ± 1.1

1.1 ± 0.7

0.7 ± 0.2*

Dofetilide

ȃPP

713.8 ± 120.3***

809.7 ± 141.8***

885.9 ± 166.6*,***

ȃRR

1501.0 ± 333.2***

1000.0 ± 0.0*

ȃQRS

100.9 ± 4.6***

119.6 ± 9.8*

96.9 ± 6.0**,***

ȃQT

579.7.3 ± 85.7***

612.0 ± 84.4***

565.6 ± 77.5***

ȃQTc

536.0 ± 81.7***

612.0 ± 84.4*,***

565.6 ± 77.5***

ȃJTc

435.2 ± 81.8***

492.5 ± 83.3***

468.8 ± 76.7***

ȃTp-e

177.2 ± 46.2***

174.2 ± 52.3***

172.8 ± 51.8***

ȃRV MAPD

359.0 ± 33.9***

328.2 ± 53.2***

ȃLV ARI

448.0 ± 48.5***

474.6 ± 59.0***

455.7 ± 42.7***

ȃΔMAPD

115.5 ± 45.5***

127.5 ± 47.7**,***

ȃRV STV

1.6 ± 0.6

1.8 ± 1.3

ȃLV STV

4.7 ± 0.9

3.9 ± 1.4***

4.2 ± 1.4***

ȃInducibility (%)

66 (19/29)

42 (5/12)*

20 (2/10)*

ȃAS

42.8 ± 33.0

15.4 ± 18.9*

10.9 ± 18.8*

Table 3

Open in new tab

Electrical consequences of chronic altered ventricular in IVR, RVA or CRT conditions

Baseline	IVR	RVA	CRT
ȃPP	560.3 ± 68.8	516.3 ± 77.2	533.5 ± 53.8
ȃRR	1338.0 ± 361.2	1000.0 ± 0.0*	1000.0 ± 0.0*
ȃQRS	98.8 ± 4.6	118.8 ± 10.1*	95.6 ± 5.9**
ȃQT	386.4 ± 67.0	379.6 ± 37.6	337.0 ± 24.6
ȃQTc	357.0 ± 56.5	379.6 ± 37.6	337.0 ± 24.6
ȃJTc	258.2 ± 56.2	260.8 ± 35.3	241.3 ± 24.6
ȃTp-e	82.6 ± 35.2	67.2 ± 15.0	61.9 ± 17.5
ȃRV_AT		26.9 ± 4.6	46.0 ± 6.1*
ȃLV_AT	35.8 ± 12.8	64.6 ± 8.3*	43.6 ± 8.3**
ȃΔAT		37.6 ± 8.1	−2.4 ± 9.6**
ȃRV MAPD		242.1 ± 16.0	221.6 ± 15.7**
ȃLV ARI	324.8 ± 51.0	271.2 ± 24.1*	266.0 ± 21.2*
ȃΔMAPD		30.0 ± 12.7	44.4 ± 14.7
ȃRV STV		1.1 ± 0.3	1.4 ± 0.7
ȃLV STV	3.2 ± 1.1	1.1 ± 0.7	0.7 ± 0.2*
Dofetilide
ȃPP	713.8 ± 120.3***	809.7 ± 141.8***	885.9 ± 166.6,**
ȃRR	1501.0 ± 333.2***	1000.0 ± 0.0*	1000.0 ± 0.0*
ȃQRS	100.9 ± 4.6***	119.6 ± 9.8*	96.9 ± 6.0,*
ȃQT	579.7.3 ± 85.7***	612.0 ± 84.4***	565.6 ± 77.5***
ȃQTc	536.0 ± 81.7***	612.0 ± 84.4,**	565.6 ± 77.5***
ȃJTc	435.2 ± 81.8***	492.5 ± 83.3***	468.8 ± 76.7***
ȃTp-e	177.2 ± 46.2***	174.2 ± 52.3***	172.8 ± 51.8***
ȃRV MAPD		359.0 ± 33.9***	328.2 ± 53.2***
ȃLV ARI	448.0 ± 48.5***	474.6 ± 59.0***	455.7 ± 42.7***
ȃΔMAPD		115.5 ± 45.5***	127.5 ± 47.7,*
ȃRV STV		1.6 ± 0.6	1.8 ± 1.3
ȃLV STV	4.7 ± 0.9	3.9 ± 1.4***	4.2 ± 1.4***
ȃInducibility (%)	66 (19/29)	42 (5/12)*	20 (2/10)*
ȃAS	42.8 ± 33.0	15.4 ± 18.9*	10.9 ± 18.8*

Baseline	IVR	RVA	CRT
ȃPP	560.3 ± 68.8	516.3 ± 77.2	533.5 ± 53.8
ȃRR	1338.0 ± 361.2	1000.0 ± 0.0*	1000.0 ± 0.0*
ȃQRS	98.8 ± 4.6	118.8 ± 10.1*	95.6 ± 5.9**
ȃQT	386.4 ± 67.0	379.6 ± 37.6	337.0 ± 24.6
ȃQTc	357.0 ± 56.5	379.6 ± 37.6	337.0 ± 24.6
ȃJTc	258.2 ± 56.2	260.8 ± 35.3	241.3 ± 24.6
ȃTp-e	82.6 ± 35.2	67.2 ± 15.0	61.9 ± 17.5
ȃRV_AT		26.9 ± 4.6	46.0 ± 6.1*
ȃLV_AT	35.8 ± 12.8	64.6 ± 8.3*	43.6 ± 8.3**
ȃΔAT		37.6 ± 8.1	−2.4 ± 9.6**
ȃRV MAPD		242.1 ± 16.0	221.6 ± 15.7**
ȃLV ARI	324.8 ± 51.0	271.2 ± 24.1*	266.0 ± 21.2*
ȃΔMAPD		30.0 ± 12.7	44.4 ± 14.7
ȃRV STV		1.1 ± 0.3	1.4 ± 0.7
ȃLV STV	3.2 ± 1.1	1.1 ± 0.7	0.7 ± 0.2*
Dofetilide
ȃPP	713.8 ± 120.3***	809.7 ± 141.8***	885.9 ± 166.6,**
ȃRR	1501.0 ± 333.2***	1000.0 ± 0.0*	1000.0 ± 0.0*
ȃQRS	100.9 ± 4.6***	119.6 ± 9.8*	96.9 ± 6.0,*
ȃQT	579.7.3 ± 85.7***	612.0 ± 84.4***	565.6 ± 77.5***
ȃQTc	536.0 ± 81.7***	612.0 ± 84.4,**	565.6 ± 77.5***
ȃJTc	435.2 ± 81.8***	492.5 ± 83.3***	468.8 ± 76.7***
ȃTp-e	177.2 ± 46.2***	174.2 ± 52.3***	172.8 ± 51.8***
ȃRV MAPD		359.0 ± 33.9***	328.2 ± 53.2***
ȃLV ARI	448.0 ± 48.5***	474.6 ± 59.0***	455.7 ± 42.7***
ȃΔMAPD		115.5 ± 45.5***	127.5 ± 47.7,*
ȃRV STV		1.6 ± 0.6	1.8 ± 1.3
ȃLV STV	4.7 ± 0.9	3.9 ± 1.4***	4.2 ± 1.4***
ȃInducibility (%)	66 (19/29)	42 (5/12)*	20 (2/10)*
ȃAS	42.8 ± 33.0	15.4 ± 18.9*	10.9 ± 18.8*

Values are represented as mean ± SD.

N = 29 for IVR (n = 4 for intracardiac measurements), n = 12 for RVA and n = 10 for CRT.

ARI, activation recovery interval; AS, arrhythmia score; CRT, cardiac resynchronization therapy; IVR, idioventricular rhythm; LVAT, left ventricular activation time; MAPD, monophasic action potential duration; LV STV, Short-term variability of repolarization; RV, right ventricle; RVA, right ventricular apex paced; RVAT, right ventricular activation time; RV STV, short-term variability of repolarization; ΔAT, interventricular differences in activation time (calculated as LV_AT – RV_AT); ΔMAPD, interventricular dispersion of repolarization (calculated as LV ARI–RV MAPD).

*P < 0.05 vs. IVR.

**P < 0.05 vs. RVA.

***P < 0.05 vs. baseline.

This Feature Is Available To Subscribers Only